source
- Moderna’s melanoma vaccine trial success sparks $45 billion market value surgeModerna’s shares jumped more than 170% after the company announced that its experimental melanoma vaccine, intismeran, met its primary goals in a Phase 3 trial. The surge added roughly $45 billion…
- Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’Boehringer Ingelheim has suspended a phase 1 trial of an investigational small molecule drug while it seeks to understand a “safety event,” although the German pharma isn't shedding light on the na…Fierce Biotech · 19h ago↗ source